Cell line · CVCL_1625
Papers60
1 to 20 of 60
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma. | Clin Pharmacol Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Anti-myeloma activity of the CXCR4 antagonist WZ811. | J Mol Med (Berl) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. | Blood Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| In vitro models of the crosstalk between multiple myeloma and stromal cells recapitulate the mild NF-κB activation observed in vivo. | Cell Death Dis | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma. | Cancer Cell Int | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway. | Clin Transl Immunology | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1625/papers